Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeTACTIC Study
2010-018353-36Phase 3Active
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Apr 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Cardiac Rejection, coronary vasculopathy and chronic kidney disease (CKD) comparing Everolimus + cyclosporine with Mycophenolate + cyclosporine (2 arms). Primary endpoint: Primary composite endpoint at 3 years. Started Apr 2010; status: active.
02
Drugs
everolimusmycophenolate mofetilmycophenolate sodiumcyclosporine
03
Conditions
Cardiac Rejectioncoronary vasculopathychronic kidney disease (CKD)
Beyond the preview
Go deeper on 2010-018353-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018353-36.